

Filippo Martinelli-Boneschi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7159687/publications.pdf>

Version: 2024-02-01

145
papers

12,909
citations

44066

48
h-index

25787

108
g-index

151
all docs

151
docs citations

151
times ranked

23082
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011, 476, 214-219.	27.8	2,400
2	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	27.0	1,548
3	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013, 45, 1353-1360.	21.4	1,213
4	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019, 365, .	12.6	710
5	Mutations in <i>LG11</i> cause autosomal-dominant partial epilepsy with auditory features. <i>Nature Genetics</i> , 2002, 30, 335-341.	21.4	555
6	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	5.3	370
7	De novo mutations in <i>ATP1A3</i> cause alternating hemiplegia of childhood. <i>Nature Genetics</i> , 2012, 44, 1030-1034.	21.4	345
8	Genomewide meta-analysis identifies novel multiple sclerosis susceptibility loci. <i>Annals of Neurology</i> , 2011, 70, 897-912.	5.3	314
9	Class II HLA interactions modulate genetic risk for multiple sclerosis. <i>Nature Genetics</i> , 2015, 47, 1107-1113.	21.4	312
10	Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls. <i>American Journal of Human Genetics</i> , 2013, 92, 854-865.	6.2	164
11	Fatigue in Multiple Sclerosis Is Associated with Abnormal Cortical Activation to Voluntary Movement—EEG Evidence. <i>NeuroImage</i> , 2001, 13, 1186-1192.	4.2	136
12	MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. <i>Journal of Neurology</i> , 2000, 247, 506-509.	3.6	122
13	Vascular endothelial growth factor gene variability is associated with increased risk for AD. <i>Annals of Neurology</i> , 2005, 57, 373-380.	5.3	115
14	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018, 175, 1679-1687.e7.	28.9	115
15	Ceramide levels are inversely associated with malignant progression of human glial tumors. <i>Glia</i> , 2002, 39, 105-113.	4.9	112
16	Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment. <i>Multiple Sclerosis Journal</i> , 2018, 24, 459-471.	3.0	105
17	Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised serum creatine kinase levels. <i>Journal of Neurology</i> , 2002, 249, 305-311.	3.6	100
18	Evaluation of Polyneuropathy Markers in Type 1 Diabetic Kidney Transplant Patients and Effects of Islet Transplantation. <i>Diabetes Care</i> , 2007, 30, 3063-3069.	8.6	98

#	ARTICLE	IF	CITATIONS
19	Lifetime and actual prevalence of pain and headache in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 514-521.	3.0	97
20	MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. <i>Neuroscience Letters</i> , 2012, 508, 4-8.	2.1	95
21	NLRP3 inflammasome is associated with the response to IFN- β in patients with multiple sclerosis. <i>Brain</i> , 2015, 138, 644-652.	7.6	93
22	The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. <i>Journal of Neuroimmunology</i> , 2013, 260, 99-106.	2.3	88
23	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	3.7	86
24	Next Generation Sequencing of Pooled Samples: Guideline for Variants™ Filtering. <i>Scientific Reports</i> , 2016, 6, 33735.	3.3	81
25	A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1076-1083.	3.0	77
26	Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. <i>Neurology: Genetics</i> , 2016, 2, e87.	1.9	76
27	Interleukin-1B polymorphism is associated with age at onset of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 927-931.	3.1	75
28	Mitoxantrone for multiple sclerosis. <i>The Cochrane Library</i> , 2013, , CD002127.	2.8	75
29	Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. <i>Multiple Sclerosis Journal</i> , 2003, 9, 349-355.	3.0	72
30	MGAT5 alters the severity of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010, 220, 120-124.	2.3	72
31	Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. <i>Oncogene</i> , 2015, 34, 2094-2102.	5.9	72
32	IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. <i>Genes and Immunity</i> , 2010, 11, 397-405.	4.1	70
33	Surgery for intracranial meningiomas in the elderly: a clinical-radiological grading system as a predictor of outcome. <i>Journal of Neurosurgery</i> , 2005, 102, 290-294.	1.6	69
34	Prostaglandin D2 synthase/GPR44: a signaling axis in PNS myelination. <i>Nature Neuroscience</i> , 2014, 17, 1682-1692.	14.8	66
35	Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2019, 18, 155-164.	10.2	63
36	Cerebral grey matter pathology and fatigue in patients with multiple sclerosis: a preliminary study. <i>Journal of the Neurological Sciences</i> , 2002, 194, 71-74.	0.6	60

#	ARTICLE	IF	CITATIONS
37	Mitochondrial DNA sequence variation in multiple sclerosis. <i>Neurology</i> , 2015, 85, 325-330.	1.1	60
38	Four New Families with Autosomal Dominant Partial Epilepsy with Auditory Features: Clinical Description and Linkage to Chromosome 10q24. <i>Epilepsia</i> , 2002, 43, 60-67.	5.1	59
39	Forceps minor damage and co-occurrence of depression and fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1633-1640.	3.0	59
40	An APOE Haplotype Associated with Decreased β 4 Expression Increases the Risk of Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 235-245.	2.6	58
41	Genetics can contribute to the prognosis of Brugada syndrome: a pilot model for risk stratification. <i>European Journal of Human Genetics</i> , 2013, 21, 911-917.	2.8	58
42	Role of <i>hnRNP-A1</i> and miR-590-3p in Neuronal Death: Genetics and Expression Analysis in Patients with Alzheimer Disease and Frontotemporal Lobar Degeneration. <i>Rejuvenation Research</i> , 2011, 14, 275-281.	1.8	57
43	A genome-wide association study in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1384-1394.	3.0	57
44	Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population. <i>PLoS ONE</i> , 2010, 5, e9287.	2.5	56
45	Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. <i>Neurobiology of Aging</i> , 2006, 27, 770.e1-770.e5.	3.1	54
46	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015, 138, 632-643.	7.6	54
47	HIF-1 α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. <i>Blood</i> , 2016, 127, 1987-1997.	1.4	52
48	Sleep breathing disorders in 40 Italian patients with Myotonic dystrophy type 1. <i>Neuromuscular Disorders</i> , 2012, 22, 219-224.	0.6	51
49	DDIT4/REDD1/RTP801 Is a Novel Negative Regulator of Schwann Cell Myelination. <i>Journal of Neuroscience</i> , 2013, 33, 15295-15305.	3.6	51
50	Long-Term Coronavirus Disease 2019 Complications in Inpatients and Outpatients: A One-Year Follow-up Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab384.	0.9	47
51	Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease. <i>PLoS Genetics</i> , 2019, 15, e1008180.	3.5	46
52	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	2.9	46
53	Retrospective study of a large population of patients affected with mitochondrial disorders: clinical, morphological and molecular genetic evaluation. <i>Journal of Neurology</i> , 2001, 248, 778-788.	3.6	45
54	Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. <i>Neurobiology of Aging</i> , 2013, 34, 1711.e7-1711.e13.	3.1	43

#	ARTICLE	IF	CITATIONS
55	Evidence and age-related distribution of mtDNA D-loop point mutations in skeletal muscle from healthy subjects and mitochondrial patients. <i>Journal of the Neurological Sciences</i> , 2002, 202, 85-91.	0.6	42
56	Absence of angiogenic genes modification in Italian ALS patients. <i>Neurobiology of Aging</i> , 2008, 29, 314-316.	3.1	41
57	Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: Evidence from a safety study with pilot efficacy measures in adult dystrophic patients. <i>Pharmacological Research</i> , 2012, 65, 472-479.	7.1	40
58	Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2284-93.	7.1	39
59	Peripheral nerve morphogenesis induced by scaffold micropatterning. <i>Biomaterials</i> , 2014, 35, 4035-4045.	11.4	39
60	A pharmacogenetic study implicates <i>SLC9a9</i> in multiple sclerosis disease activity. <i>Annals of Neurology</i> , 2015, 78, 115-127.	5.3	39
61	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2005, 165, 192-200.	2.3	38
62	Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study. <i>Neurological Sciences</i> , 2016, 37, 235-242.	1.9	38
63	Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. <i>Annals of Neurology</i> , 2018, 84, 51-63.	5.3	38
64	Oxidative Imbalance in Different Neurodegenerative Diseases with Memory Impairment. <i>Neurodegenerative Diseases</i> , 2011, 8, 129-137.	1.4	37
65	The mirror neuron system and the strange case of Broca's area. <i>Human Brain Mapping</i> , 2015, 36, 1010-1027.	3.6	37
66	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016, 134, 281-294.	4.2	36
67	Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 745-749.	2.6	35
68	Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. <i>Scientific Reports</i> , 2017, 7, 43718.	3.3	35
69	Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1268-1269.	3.0	35
70	Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 520-526.	2.0	34
71	Early involvement of cellular stress and inflammatory signals in the pathogenesis of tubulointerstitial kidney disease due to UMOD mutations. <i>Scientific Reports</i> , 2017, 7, 7383.	3.3	33
72	The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation. <i>Leukemia</i> , 2020, 34, 257-270.	7.2	33

#	ARTICLE	IF	CITATIONS
73	Role of OLR1 and Its Regulating hsa-miR369-3p in Alzheimer's Disease: Genetics and Expression Analysis. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 787-793.	2.6	31
74	Pharmacogenetic study of long-term response to interferon- β treatment in multiple sclerosis. <i>Pharmacogenomics Journal</i> , 2017, 17, 84-91.	2.0	31
75	Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. <i>Frontiers in Immunology</i> , 2017, 8, 321.	4.8	30
76	The 129 codon polymorphism of the Prion Protein gene influences earlier cognitive performance in Down syndrome subjects. <i>Journal of Neurology</i> , 2003, 250, 688-692.	3.6	29
77	Astrocytes acquire resistance to iron-dependent oxidative stress upon proinflammatory activation. <i>Journal of Neuroinflammation</i> , 2013, 10, 130.	7.2	29
78	GRN Variability Contributes to Sporadic Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 171-177.	2.6	28
79	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. <i>Pharmacogenomics Journal</i> , 2017, 17, 312-318.	2.0	28
80	An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2003, 9, 467-471.	3.0	27
81	Clinical and MRI predictors of response to interferon- β and glatiramer acetate in relapsing-remitting multiple sclerosis patients. <i>European Journal of Neurology</i> , 2013, 20, 1060-1067.	3.3	27
82	Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1431-1442.	3.0	27
83	Association of Genetic Markers with CSF Oligoclonal Bands in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2013, 8, e64408.	2.5	27
84	Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1490-1499.	3.0	26
85	A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility. <i>Genes and Immunity</i> , 2014, 15, 126-132.	4.1	26
86	Functional and structural plasticity following action observation training in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1472-1487.	3.0	26
87	Human glioma tumors express high levels of chemokine receptor CX3CR1. <i>European Cytokine Network</i> , 2010, 21, 27-33.	2.0	26
88	Motor evoked potentials in a mouse model of chronic multiple sclerosis. <i>Muscle and Nerve</i> , 2006, 33, 265-273.	2.2	25
89	COL6A5 variants in familial neuropathic chronic itch. <i>Brain</i> , 2017, 140, aww343.	7.6	25
90	Unraveling gene expression profiles in peripheral motor nerve from amyotrophic lateral sclerosis patients: insights into pathogenesis. <i>Scientific Reports</i> , 2016, 6, 39297.	3.3	24

#	ARTICLE	IF	CITATIONS
91	Linkage Analysis and Disease Models in Benign Familial Infantile Seizures: A Study of 16 Families. <i>Epilepsia</i> , 2006, 47, 1029-1034.	5.1	23
92	Movement preparation is affected by tissue damage in multiple sclerosis: Evidence from EEG event-related desynchronization. <i>Clinical Neurophysiology</i> , 2005, 116, 1515-1519.	1.5	22
93	Follow-up of a large population of asymptomatic/oligosymptomatic hyperckemic subjects. <i>Journal of Neurology</i> , 2006, 253, 1399-1403.	3.6	22
94	Patient-Reported Symptoms and Sequelae 12 Months After COVID-19 in Hospitalized Adults: A Multicenter Long-Term Follow-Up Study. <i>Frontiers in Medicine</i> , 2022, 9, 834354.	2.6	22
95	Impact of fatigue on the efficacy of rehabilitation in multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 835-839.	3.6	21
96	The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy. <i>International Journal of Cardiology</i> , 2021, 324, 249-254.	1.7	21
97	The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. <i>Multiple Sclerosis Journal</i> , 2004, 10, 341-347.	3.0	20
98	Association study of a new polymorphism in the PECAM-1 gene in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2000, 104, 174-178.	2.3	19
99	Pharmacogenomic study in patients with multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e154.	6.0	19
100	Impact of MS genetic loci on familial aggregation, clinical phenotype, and disease prediction. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e129.	6.0	18
101	CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1203-1208.	2.6	18
102	Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. <i>European Journal of Neurology</i> , 2018, 25, 934.	3.3	18
103	Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?. <i>Journal of Neuro-Oncology</i> , 2007, 84, 71-77.	2.9	17
104	Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. <i>Genes and Immunity</i> , 2010, 11, 497-503.	4.1	17
105	Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. <i>Neuroscience Letters</i> , 2012, 530, 155-160.	2.1	17
106	Evaluation of molecular inversion probe versus TruSeq® custom methods for targeted next-generation sequencing. <i>PLoS ONE</i> , 2020, 15, e0238467.	2.5	17
107	Posterior reversible encephalopathy syndrome and COVID-19: A series of 6 cases from Lombardy, Italy. <i>ENeurologicalSci</i> , 2021, 22, 100306.	1.3	17
108	Pharmacogenetics of autoimmune diseases: Research issues in the case of Multiple Sclerosis and the role of IFN- β . <i>Journal of Autoimmunity</i> , 2005, 25, 1-5.	6.5	15

#	ARTICLE	IF	CITATIONS
109	Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation. <i>Medicina (Lithuania)</i> , 2020, 56, 572.	2.0	14
110	Inverse correlation of genetic risk score with age at onset in bout-onset and progressive-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1463-1467.	3.0	13
111	COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper. <i>European Journal of Neurology</i> , 2022, 29, 2163-2172.	3.3	13
112	Failure to Replicate an Association of rs5984894 SNP in the PCDH11X Gene in a Collection of 1,222 Alzheimer's Disease Affected Patients. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 385-388.	2.6	11
113	Short and Long Term Variation in Ultraviolet Radiation and Multiple Sclerosis. <i>International Journal of Environmental Research and Public Health</i> , 2012, 9, 685-697.	2.6	11
114	Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 862-870.	3.0	11
115	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 802-811.	3.0	11
116	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1507-1510.	3.0	11
117	CSF metabolites in the differential diagnosis of Alzheimer's disease from frontal variant of frontotemporal dementia. <i>Neurological Sciences</i> , 2012, 33, 973-977.	1.9	10
118	The burden of multiple sclerosis variants in continental Italians and Sardinians. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1385-1395.	3.0	10
119	MGAT5 and disease severity in progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011, 230, 143-147.	2.3	9
120	No C9orf72 repeat expansion in patients with primary progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 192-195.	2.0	9
121	Untangling Extracellular Proteasome-Osteopontin Circuit Dynamics in Multiple Sclerosis. <i>Cells</i> , 2019, 8, 262.	4.1	9
122	Evidence for use of glatiramer acetate in multiple sclerosis. <i>Lancet Neurology</i> , The, 2005, 4, 75-76.	10.2	8
123	No evidence of ATP1A2 involvement in 12 multiplex Italian families with benign familial infantile seizures. <i>Neuroscience Letters</i> , 2005, 388, 71-74.	2.1	8
124	A Strong Anti-Inflammatory Signature Revealed by Liver Transcription Profiling of Tmprss6 ^{-/-} Mice. <i>PLoS ONE</i> , 2013, 8, e69694.	2.5	8
125	Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis. <i>Neurological Sciences</i> , 2014, 35, 789-791.	1.9	8
126	Laser capture microdissection for transcriptomic profiles in human skin biopsies. <i>BMC Molecular Biology</i> , 2018, 19, 7.	3.0	7

#	ARTICLE	IF	CITATIONS
127	A pharmacogenetic study implicates NINJ2 in the response to Interferon- $\hat{2}$ in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1074-1082.	3.0	5
128	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 73-76.	2.0	4
129	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 447-453.	2.1	4
130	Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 591395.	2.4	4
131	An Investigation of the Role of Common and Rare Variants in a Large Italian Multiplex Family of Multiple Sclerosis Patients. <i>Genes</i> , 2021, 12, 1607.	2.4	4
132	Genomic and functional evaluation of TNFSF14 in multiple sclerosis susceptibility. <i>Journal of Genetics and Genomics</i> , 2021, 48, 497-507.	3.9	3
133	Contribution of Rare and Low-Frequency Variants to Multiple Sclerosis Susceptibility in the Italian Continental Population. <i>Frontiers in Genetics</i> , 2021, 12, 800262.	2.3	3
134	Transmembrane Protein 106B Gene (TMEM106B) Variability and Influence on Progranulin Plasma Levels in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 757-761.	2.6	2
135	Impact of multiple sclerosis risk loci in postinfectious neurological syndromes. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102326.	2.0	2
136	The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults. <i>Journal of Clinical Medicine</i> , 2021, 10, 686.	2.4	2
137	Assessment of the genetic contribution to brain magnetic resonance imaging lesion load and atrophy measures in multiple sclerosis patients. <i>European Journal of Neurology</i> , 2021, 28, 2513-2522.	3.3	2
138	A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility. <i>Journal of Neurology</i> , 2022, 269, 4510-4522.	3.6	2
139	LETTER TO THE EDITOR. <i>Brain Pathology</i> , 2012, 22, 79-79.	4.1	1
140	Multiple sclerosis progression is not associated with birth timing in Italy. <i>Journal of the Neurological Sciences</i> , 2014, 346, 194-196.	0.6	1
141	Assessing Functional Decline in Neurological Diseases Clinical Trials: Duration of Follow-Up - The Case of Multiple Sclerosis. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 93-100.	2.8	1
142	Response to the commentary "The effect of C9orf72 intermediate repeat expansions in neurodegenerative and autoimmune diseases" by Biasiotto G and Zanella I. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 79-80.	2.0	1
143	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDIatric Italian Genetic and enviRonment ExposurE Questionnaire). <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110590.	1.0	1
144	Advances in Neuroimmunology: From Bench to Bedside. <i>Autoimmune Diseases</i> , 2014, 2014, 1-2.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Impact of SARS-CoV-2 infection on acute intracerebral haemorrhage in northern Italy. Journal of the Neurological Sciences, 2021, 426, 117479.	0.6	0